Diabetic Retinopathy (DR) is a leading cause of blindness worldwide, driven by high blood sugar levels, which damage the blood vessels in the eye. A key component of this damage is the loss of pericytes, specialized cells that stabilize blood vessels and keep them functioning properly. Without pericytes, blood vessels become leaky and dysfunctional, rapidly accelerating inflammation and vision loss. Current treatments mostly target late-stage disease, leaving a critical gap for early intervention. This project investigates a nanotherapeutic approach using resveratrol (RSV), a natural anti-inflammatory compound, packaged inside tiny nanoparticles called PEG-b-PPS micelles. These micelles are designed to efficiently deliver RSV to diseased vasculature while protecting it from degradation in the body. To test this approach, we established a laboratory model of DR by co-culturing both human pericytes and endothelial cells (the cells lining blood vessels) and exposing them to high glucose levels to simulate the diabetic eye. High glucose triggered the expression of several disease marker genes, including VEGF and PDGF. These proteins drive abnormal blood vessel growth by causing pericytes to detach from endothelial cells, mimicking early DR progression. When treated with RSV-loaded micelles, pericyte dropout was significantly reduced, and disease-related gene expression was attenuated. The micelles themselves were small and stable, achieving an 83% drug encapsulation efficiency. Our results suggest that RSV/PEG-b-PPS micelles could serve as an effective early-stage therapeutic strategy for diabetic retinopathy, and future work will explore further co-culture models and animal trials.